Co-Codamol Dependency: A Personal Journey and a Systemic Failure

For two decades, Chloe Montgomery's life revolved around a single, unspoken truth: she was dependent on co-codamol. Now 36 and living near Glasgow, the property sales executive recalls how her addiction began in her teens, when a prescription for painkillers to manage migraines quickly spiraled into something far more insidious. "They gave me that light, fuzzy feeling," she says, describing the initial high of the medication. "It was like having a high, I suppose." But what started as a medical solution to a debilitating condition soon became a crutch, one she couldn't imagine living without.

How many people, she wonders, are forced into similar situations by a system that prioritizes convenience over caution? Her GP, she says, never questioned the long-term use of co-codamol. "They just left me on them for years," she explains. "There was no review. No conversation about tapering off or trying alternatives." This lack of oversight, she argues, is a glaring gap in how prescription drugs are managed. "You're masking your life," she says, "like a blanket over you. It's just a constant fuzziness. You can't concentrate."

Her family was aware of her daily pill routine but never suspected the depth of her dependency. "They probably think I could stop tomorrow if I wanted to," she says, though the reality is far more complicated. She would take between eight and 10 tablets a day, often every two and a half hours as her body built tolerance. "I'd use them to get through the workday," she admits. "There were days when I'd be driving, drop my kids at school, and realize halfway I'd forgotten my pills. I'd have to turn back and go get them."

Then came the national shortage of co-codamol in early 2026—a crisis that forced her into agonizing withdrawal. The NHS had warned for years about the risks of prolonged opioid use, yet here was a system that left individuals like Montgomery with no safety net when supply chains faltered. "I was shocked," she says. "It was a sense of panic. You feel dependent on them, and then suddenly they're gone."

The shortage, which began in January 2026, was not an isolated incident. A medicine supply notification had already been issued, warning that co-codamol 30mg/500mg tablets would be limited until summer. The NHS advised gradual dose reductions, but for someone like Montgomery, the sudden unavailability of her medication was a death sentence to her routine. "You're left with no choice but to confront the addiction," she says. "It's not just about the pills—it's about the fear of what happens when you stop."

Co-codamol, a combination of codeine and paracetamol, is a double-edged sword. Codeine, an opioid, is inherently addictive, while paracetamol poses severe risks to the liver and kidneys if taken in excess. The NHS explicitly warns against long-term use, yet millions are prescribed it without adequate monitoring. Montgomery's story raises a chilling question: How many others are trapped in similar cycles, their addictions hidden behind a veneer of medical legitimacy?

Her journey to recovery was not easy. She ended up hospitalized with a perforated bowel, a consequence of years of dependency and the physical toll of withdrawal. "It was agonizing," she says. "You're not just dealing with the pain of withdrawal—you're dealing with the guilt of what you've done to your body."

As the shortage continues, Montgomery's experience serves as a stark reminder of the fragility of the healthcare system. When supply chains fail, who is left to pick up the pieces? And more importantly, how many lives are quietly unraveling under the weight of policies that prioritize efficiency over individual well-being? The answer, she suggests, lies in the stories of those who have already fallen through the cracks.

Codeine, a medication often prescribed for pain relief and anxiety, has long been praised for its ability to soothe both physical and emotional distress. Many users describe the drug as a temporary escape from reality, a way to "take the edge off" the pressures of daily life. Jan Gerber, founder of the Swiss rehab clinic Paracelus Recovery, has noted that the psychological grip of codeine can be just as formidable as its physical effects. He explains that addiction, tolerance, and dependence develop rapidly—within weeks, users may find themselves deeply entangled in a cycle they struggle to break. For some, the drug's calming influence and sleep-enhancing properties make it particularly hard to resist, especially for those grappling with high stress or emotional turmoil.

The story of one woman, who has spent years relying on co-codamol, illustrates the challenges of overcoming such an addiction. After receiving her final prescription, she was forced to confront the reality of withdrawal. Describing the experience as "horrific," she recounted symptoms like night sweats, severe headaches, and physical tremors. Despite the agony, she remains resolute in her decision to avoid relapse. "I know it's going to be tough," she said, "but I need to get through this." Her struggle highlights a broader dilemma: how to wean off a medication that has become both a crutch and a necessity.

Her journey is not without precedent. In 2018, she attempted to quit co-codamol after suffering complications from stomach ulcers and a perforated bowel—an ordeal she suspects may have been linked to prolonged use of the drug. Though she initially sought to break free, her addiction proved too strong. Now, with the help of her GP, she has turned to alternative treatments like Ibuprofen gel for pain caused by a slipped disc. Yet, despite the physical discomfort and years of dependency, she is determined not to return to lower-strength versions of the medication. "I've never tried to come off them before," she admitted, "but I know this is the best path forward."

The woman's decision to document her withdrawal process on TikTok has sparked a wave of public interest. One video, titled "Day three of no co-codamol," has garnered over 113,000 views, offering a raw glimpse into the emotional and physical toll of quitting. In the clip, she acknowledges the difficulty of the journey but expresses hope that the ongoing shortage of prescription painkillers may ultimately help others confront their own dependencies. "It's my fault for keeping taking them," she said, "but I believe those who prescribe them also need to take responsibility."

Her words reflect a growing conversation about the role of healthcare providers in managing addiction. As a mother of two, she worries about the long-term consequences of overprescribing opioids, even as she grapples with her own past reliance on the drug. "I'd be furious if my child was prescribed opioids to that extent," she said. Her experience underscores a critical need for open dialogue about addiction—both for those struggling and for the professionals who guide them. She urges others to seek support, whether through gradual weaning or abrupt cessation. "Talk to someone," she insisted. "It's not easy, but it's worth it.